Trial Profile
Phase II Non-randomized Study of a Atezolizumab (MPDL3280A) in Combination With Carboplatin Plus Pemetrexed in Patients Who Are Chemotherapy-naive and Have Stage IV Non-squamous Non-small Cell Lung Cancer Twith Asymptomatic Brain Metastasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ATEZO-BRAIN
- 12 Aug 2023 Results published in the Journal of Clinical Oncology
- 07 Jun 2022 Updated analysis of this study was presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 04 May 2022 Planned End Date changed from 15 Dec 2022 to 31 Dec 2022.